Prospective Observation of Cardiac Safety With Proteasome Inhibition
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib (Primary)
- Indications Heart failure; Multiple myeloma
- Focus Adverse reactions
- Acronyms PROTECT
- 18 Apr 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Aug 2017.
- 08 Dec 2014 Planned primary completion date changed from 1 Jul 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
- 08 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.